⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Ergothioneine
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-08 — Ergothioneine as a potential geroprotector: Targeting molecular hallmarks of ageing and age-related diseases.: 2005–2025 systematic review consolidating mechanistic, preclinical, and longitudinal human data positions ergothioneine — selectively accumulated via OCTN1 — as a multi-hallmark geroprotector candidate and potential aging biomarker; no new primary trial data, calls for rigorous clinical healthspan evaluation. [expert-opinion] (novelty: 3)
- 2026-07-03 — PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.: PROMETHEUS protocol reserves ergothioneine as an optional mid-intervention add-on for participants with inadequate cognitive response; conditional design element, no efficacy data. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
NVTIA® Ergothioneine for Healthy Aging and Skin Health
06-aug-2026
novelty 2
per-area 2
introduces
PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.
03-jul-2026
novelty 3
per-area 3
strengthens
Ergothioneine as a potential geroprotector: Targeting molecular hallmarks of ageing and age-related diseases.
08-may-2026
novelty 3
per-area 3
strengthens